Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Equities researchers at Oppenheimer Holdings decreased their FY2021 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a report released on Wednesday. Oppenheimer Holdings analyst L. Cann now expects that the company will earn $1.07 per share for the year, down from their prior estimate of $1.10.
SYRS has been the subject of a number of other research reports. JMP Securities downgraded Syros Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 10th. Wedbush reissued an “outperform” rating and set a $22.84 price objective (down previously from $25.00) on shares of Syros Pharmaceuticals in a report on Thursday, August 10th. ValuEngine raised Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Zacks Investment Research cut Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, Cowen and Company reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $26.14.
TRADEMARK VIOLATION NOTICE: “Oppenheimer Holdings Comments on Syros Pharmaceuticals, Inc.’s FY2021 Earnings (SYRS)” was originally reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/oppenheimer-holdings-comments-on-syros-pharmaceuticals-inc-s-fy2021-earnings-syrs.html.
Shares of Syros Pharmaceuticals (SYRS) opened at $11.34 on Friday. Syros Pharmaceuticals has a 1-year low of $10.22 and a 1-year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.53).
Several institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of Syros Pharmaceuticals in the third quarter valued at about $975,000. Trexquant Investment LP purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $282,000. JPMorgan Chase & Co. raised its position in Syros Pharmaceuticals by 15.9% during the third quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after purchasing an additional 17,330 shares during the period. Russell Investments Group Ltd. purchased a new stake in Syros Pharmaceuticals during the third quarter valued at approximately $133,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Syros Pharmaceuticals by 17.7% during the third quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock valued at $520,000 after buying an additional 5,305 shares during the last quarter. Institutional investors and hedge funds own 59.76% of the company’s stock.
In related news, Director Richard A. Young sold 3,282 shares of Syros Pharmaceuticals stock in a transaction on Monday, August 14th. The stock was sold at an average price of $22.00, for a total value of $72,204.00. Following the completion of the sale, the director now owns 420,101 shares of the company’s stock, valued at $9,242,222. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 33.60% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.